AzTrials
AzTrials

Esophageal CancerPhase 1NCT02205463

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

A Phase 1 study testing KD019 in people with Esophageal Cancer and Stomach Cancer, run by NYU Langone Health at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and efficacy of KD019 in combination with trastuzumab and mFOLFOX-6. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Esophageal Cancer, Stomach Cancer
What is being tested?
KD019
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
Dec 2014to Jul 2017
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:
  • Pathologically confirmed diagnosis of adenocarcinoma of stomach, GEJ or esophagus (central confirmation is not required). Primary tumor or metastatic lesion must be HER2+ documented as HER2 gene amplification by FISH as positive (HER2:CEP17 ratio of ≥2.0) or IHC 3+.
  • Metastatic or unresectable adenocarcinoma of stomach, GEJ, or esophagus that is evaluable or that is measurable for response as per RECIST 1.1 criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral computed tomography (CT) scan.
  • Adult subjects greater than 18 years of age
  • Patients who received postoperative adjuvant therapy with a single-agent fluoropyrimidine and radiation are eligible.
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1.
Show all 21Show fewer
  • Adequate organ and bone marrow functions defined as follows:
  • oAbsolute neutrophil count >1,500 cells/ul
  • Platelets >100,000/ul
  • Hemoglobin >9.0g/dl
  • INR < or equal to 1.5 or INR < or equal to 3 if patient is on warfarin
  • Serum creatinine < or equal to 1.5 times upper limit of normal (ULN) or calculated creatinine clearance (CRCL) > or equal to 60ml/min
  • Serum electrolytes within the normal range (per institution standard) during screening.
  • Total bilirubin less than or equal to 1.5 times upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < or equal to 3 times ULN
  • Albumin > or equal to 3g/dL
  • No history of another malignancy in the past 5 years, except treated non-melanoma skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix
  • No coexisting medical problems of sufficient severity to limit compliance with the study
  • Ability to understand and sign a written informed consent document. Patient must have willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
  • Female subjects of childbearing potential must have a negative serum pregnancy test prior to study entry (positive urine tests are to be confirmed by serum test).
  • Female subjects of childbearing potential and males must agree to use a highly effective method of contraception (<1% per year failure rate) for the duration of study treatment and for six months after discontinuation of the study drug. Highly effective birth control methods include implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, or vasectomy for males.

Who cannot join

  • Prior treatment chemotherapy or HER2-directed therapy for metastatic gastric, GEJ or esophageal adenocarcinoma chemotherapy.
  • Prior peri-operative therapy with a platinum-containing regimen.
  • Angina secondary to fluoropyrimidine therapy in the adjuvant setting
  • Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable/evaluable disease.
  • Major surgery within 4 weeks prior to the first dose of KD019
  • Left ventricular ejection fraction (EF) <50% at baseline as measured by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO).
Show all 41Show fewer
  • Treatment with chronic immunosuppressants (e.g. cyclosporine following transplantation)
  • Current known active infection with HIV, hepatitis B or C viruses
  • Uncontrolled systemic disease
  • Brain metastases that are:
  • Untreated or
  • Progressive or
  • Have required any type of therapy (including radiation, surgery, steroids or anticonvulsant therapy) to control symptoms from brain metastases within 60 days prior to the first study treatment
  • Leptomeningeal
  • Hemorrhagic
  • Subject has evidence of pre-existing idiopathic pulmonary fibrosis on CT scan at baseline
  • History of an invasive secondary primary malignancy diagnosed within the previous 3 years, except for appropriately treated stage I endometrial or cervical carcinoma, prostate carcinoma treated surgically or non-melanoma skin cancer.
  • No other non-protocol antineoplastic agents will be permitted during this study
  • Patients may not be receiving any other investigational agents.
  • Women who are pregnant or lactating.
  • Subject has any of the following EKG criteria:
  • Corrected QT interval (QTc) of >0.47 seconds
  • Finding of a left bundle branch block or right bundle bunch block
  • Bradycardia defined as a heart rate of <50 beats per minute (bpm)
  • Presence of a pacemaker or implantable cardioverter defibrillator (ICD)
  • History of sustained ventricular arrhythmias (subjects with a history of atrial arrhythmias should be discussed with the sponsor before entry into the study)
  • Family history of congenital long QT syndrome or unexplained sudden death.
  • Moderate or severe pulmonary dysfunction
  • History of clinically significant cardiac dysfunction including:
  • Unstable angina
  • History of myocardial infarction (MI) within 6 months prior to first study treatment
  • History of symptomatic CHF (grade >3 by NCI CTCAE or Class >II by New York Heart Association (NYHA) criteria or serious cardiac arrhythmia requiring treatment, with the exception of atrial fibrillation and paroxysmal supraventricular tachycardia
  • Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 and/or diastolic blood pressure (DBP) ≥ 100 despite maximal medical therapy.
  • Subject requires treatment with drugs known to be associated with torsades de pointes or significant QT interval prolongation.
  • Patients will be eligible for the study if they discontinue any medications listed in one week prior to registration and study enrollment.
  • Stable regimen of antidepressants of the SSRI class is allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline and fluoxetine)
  • Use of cytochrome P450 enzyme-inducing anti-epileptic drugs (such as phenytoin, carbamazepine or phenobarbital) is not allowed.
  • Subject has a serum potassium or magnesium level outside the normal range despite repletion.
  • Has gastrointestinal tract disease resulting in an inability to take or absorb oral medication.
  • Inclusion or exclusion of patients on other medications, or severe acute/chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results will be at the judgment of the study investigator.
  • Subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • NYU Langone Medical Center

    New York, New York, 10016

Other trials in United States

About this study

Official title: A Phase Ib Study of KD019 Plus Trastuzumab in Patients With HER2 Overexpressed or Amplified Metastatic or Unresectable Adenocarcinoma of Esophagus, Gastroesophageal Junction and Stomach

This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and efficacy of KD019 in combination with trastuzumab and mFOLFOX-6.

Read the detailed description

This is an open-label, single-arm, dose-escalation phase Ib study to determine the safety, maximum tolerated dose (MTD) and efficacy of KD019, a multi kinase inhibitor of EGFR, HER2, Src and VEGFR2, in combination with trastuzumab and mFOLFOX-6 for patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic or unresectable adenocarcinoma of esophagus, gastroesophageal junction or stomach.

Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and maximum tolerated dose of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.

Hypothesis A) KD019, a small molecule inhibitor of multiple receptor tyrosine kinases including EGFR, HER2, VEGFR-2 and Src, can be safely added, in an effective dose, to the every 2 week schedule of mFOLFOX-6 + trastuzumab for patients with metastatic or unresectable HER2+ adenocarcinoma of esophagus, GEJ or stomach

  1. When added to mFOLFOX-6 + trastuzumab, KD019will increase response duration, progression free survival

Primary objective:

To assess the safety, tolerability, maximum tolerated dose (MTD), recommended phase II dosing (RP2D) of KD019 in combination of trastuzumab and mFOLFOX-6

Secondary objectives:

  1. To characterize the pharmacokinetics (PK) parameters of KD019 administered once daily in combination with every 2 week mFOLFOX-6 and trastuzumab in subjects with metastatic or unresectable HER2+ adenocarcinoma of the esophagus, gastroesophageal junction (GEJ) and stomach.
  2. To evaluate tumor biopsy specimens pre- and post- treatment with KD019 and trastuzumab for changes in target receptors and correlate with response
Being tested
KD019
Keywords
Esophagus, Gastroesophageal Junction, Stomach, Gastric, Cancer, HER2, Metastatic, Adenocarcinoma
Medical subject headings
Esophageal Neoplasms, Stomach Neoplasms, Neoplasms, Neoplasm Metastasis, Adenocarcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KD019Drug

Study groups in NCT02205463
Study groupRoleWhat they receive
KD019ExperimentalPatients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
Receives: Drug: KD019

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose (MTD)

    To determine maximum tolerated dose (MTD) and RP2D of KD019 in combination with trastuzumab and mFOLFOX-6 when given to patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, GEJ or stomach (gastric).

    Measured: 28 Days

Secondary outcomes (5)

  1. Progression-Free Survival

    Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Tumor assessments will be performed using RECIST criteria (Version 1.1). Imaging scans may be done within 4 weeks prior to the first dose of study drug (baseline) and then every 12 weeks (±7 days) after the first dose of study drug until documented progression. Responses will be confirmed by repeat assessments between 28 and 35 days after the response criteria are first met.

    Measured: 3 Years

  2. Objective Response Rate

    Overall response rates are defined as partial response plus complete response. Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1). Response rates will be estimated with exact 95% confidence intervals for each dose level. Kaplan Meier curves will be used to summarize progression free survival.

    Measured: 3 Years

  3. Duration of Response

    The duration of overall response is measured from the time measurement are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1).

    Measured: 3 Years

  4. Clinical Benefit Rate

    Clinical benefit rate is defined as complete response plus partial response plus stable disease >16 weeks, and will be summarized descriptively. Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1).

    Measured: 3 Years

  5. Pharmacokinetics of KD019

    Patients will undergo pharmacokinetics at the following time points:

    • Pre- 15 minutes pre-dosing: C1 D1, C1 D15 and then D1 only starting cycle 2 and thereafter Up to and including the cycle 6 visit.
    • Post- at 1 hour, 2 hours, and 4-6 hours post dosing: C1 D1, C1 D15 and 4-6 hours post dosing only on D1 only starting cycle 2 .
    • A PK sample will also be drawn if QTc(f) interval increases to an absolute value of >500 msec. The concentration of KD019 in these samples will be used to confirm exposure to KD019 and to further characterize the plasma PK of KD019 in this subject population.
    • 30 days post treatment visit.

    Measured: Multiple

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2014 (estimated)
  2. Study startDec 2014
  3. Primary completionJul 2017 (estimated)
  4. Study completionJul 2017 (estimated)

Why it stopped: IND application withdrawn

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02205463
Sponsor's protocol ID
s14-01171
Status last verified
Jul 2014
First submitted
29 Jul 2014
Last updated
1 Aug 2014
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing KD019 in people with Esophageal Cancer and Stomach Cancer, run by NYU Langone Health at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 41 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 1 Aug 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (MTD) (time frame: 28 Days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02205463.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2014; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in